首页 > 最新文献

Transplantation Reviews最新文献

英文 中文
The effect of goal-directed fluid therapy on delayed graft function in kidney transplant recipients: A systematic review and meta-analysis 目标导向液体疗法对肾移植受者移植功能延迟的影响:系统回顾与荟萃分析。
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-02-05 DOI: 10.1016/j.trre.2024.100834
Michael P. Klonarakis , Mannat Dhillon , Emir Sevinc , Meghan J. Elliott , Matthew T. James , Ngan N. Lam , Kevin J. McLaughlin , Paul E. Ronksley , Shannon M. Ruzycki , Tyrone G. Harrison

Delayed graft function (DGF) is a common post-operative complication with potential long-term sequelae for many kidney transplant recipients, and hemodynamic factors and fluid status play a role. Fixed perioperative fluid infusions are the standard of care, but more recent evidence in the non-transplant population has suggested benefit with goal-directed fluid strategies based on hemodynamic targets. We searched MEDLINE, EMBASE, Cochrane Controlled Trials Registry and Google Scholar through December 2022 for randomized controlled trials comparing risk of DGF between goal-directed and conventional fluid therapy in adults receiving a living or deceased donor kidney transplant. Effect estimates were reported with odds ratios (OR) and pooled using random effects meta-analysis. We identified 4 studies (205 participants) that met the inclusion criteria. The use of goal-directed fluid therapy had no significant effect on DGF (OR 1.37 95% CI, 0.34–5.6; p = 0.52; I2 = 0.11). Subgroup analysis examining effects among deceased and living kidney donation did not reveal significant differences in the effects of fluid strategy on DGF between subgroups. Overall, the strength of the evidence for goal-directed versus conventional fluid therapy to reduce DGF was of low certainty. Our findings highlight the need for larger trials to determine the effect of goal-directed fluid therapy on this patient-centered outcome.

移植物功能延迟(DGF)是一种常见的术后并发症,对许多肾移植受者来说可能会造成长期后遗症,而血液动力学因素和输液状态在其中起到了一定的作用。固定的围手术期输液是护理的标准,但最近在非移植人群中出现的证据表明,根据血流动力学目标采取目标导向的输液策略是有益的。我们检索了截至 2022 年 12 月的 MEDLINE、EMBASE、Cochrane 对照试验注册中心和谷歌学术,以寻找在接受活体或死体肾移植的成人中比较目标导向和常规输液疗法的 DGF 风险的随机对照试验。用几率比 (OR) 报告效果估计值,并使用随机效应荟萃分析进行汇总。我们发现有 4 项研究(205 名参与者)符合纳入标准。使用目标导向液体疗法对 DGF 没有显著影响(OR 1.37 95% CI, 0.34-5.6; p = 0.52; I2 = 0.11)。对已故肾脏捐献者和活体肾脏捐献者的影响进行的亚组分析表明,输液策略对 DGF 的影响在不同亚组之间没有明显差异。总体而言,目标导向输液疗法与常规输液疗法在降低 DGF 方面的证据确定性较低。我们的研究结果突出表明,有必要进行更大规模的试验,以确定目标导向输液疗法对这一以患者为中心的结果的影响。
{"title":"The effect of goal-directed fluid therapy on delayed graft function in kidney transplant recipients: A systematic review and meta-analysis","authors":"Michael P. Klonarakis ,&nbsp;Mannat Dhillon ,&nbsp;Emir Sevinc ,&nbsp;Meghan J. Elliott ,&nbsp;Matthew T. James ,&nbsp;Ngan N. Lam ,&nbsp;Kevin J. McLaughlin ,&nbsp;Paul E. Ronksley ,&nbsp;Shannon M. Ruzycki ,&nbsp;Tyrone G. Harrison","doi":"10.1016/j.trre.2024.100834","DOIUrl":"10.1016/j.trre.2024.100834","url":null,"abstract":"<div><p>Delayed graft function (DGF) is a common post-operative complication with potential long-term sequelae for many kidney transplant recipients, and hemodynamic factors and fluid status play a role. Fixed perioperative fluid infusions are the standard of care, but more recent evidence in the non-transplant population has suggested benefit with goal-directed fluid strategies based on hemodynamic targets. We searched MEDLINE, EMBASE, Cochrane Controlled Trials Registry and Google Scholar through December 2022 for randomized controlled trials comparing risk of DGF between goal-directed and conventional fluid therapy in adults receiving a living or deceased donor kidney transplant. Effect estimates were reported with odds ratios (OR) and pooled using random effects meta-analysis. We identified 4 studies (205 participants) that met the inclusion criteria. The use of goal-directed fluid therapy had no significant effect on DGF (OR 1.37 95% CI, 0.34–5.6; <em>p</em> = 0.52; I<sup>2</sup> = 0.11). Subgroup analysis examining effects among deceased and living kidney donation did not reveal significant differences in the effects of fluid strategy on DGF between subgroups. Overall, the strength of the evidence for goal-directed versus conventional fluid therapy to reduce DGF was of low certainty. Our findings highlight the need for larger trials to determine the effect of goal-directed fluid therapy on this patient-centered outcome.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 2","pages":"Article 100834"},"PeriodicalIF":4.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X2400017X/pdfft?md5=1d194adabec20ab884a91886e2d974d8&pid=1-s2.0-S0955470X2400017X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139713612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Latest advances in frailty in kidney transplantation: A narrative review 肾移植中虚弱问题的最新进展:叙述性综述
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-24 DOI: 10.1016/j.trre.2024.100833
Ruth Fergie , Alexander P. Maxwell , Emma L. Cunningham

Frailty is a clinical syndrome that is characterised by decline in multiple systems with associated decreased physiological reserve and ability to respond to stressor events. It is associated with greater healthcare burden. It is common in patients with end-stage renal disease (ESRD). Kidney transplantation is considered the optimal form of renal replacement therapy for suitable patients with ESRD. However, surgery and immunosuppression are physiological stresses that can disproportionately affect frail individuals. Frailty is emerging as a potentially important risk factor in patients waitlisted for kidney transplantation. Most of the published research to date in this area comes from a single transplant centre in the USA. Frailty, as measured using the Physical Frailty Phenotype (FP), is prevalent in waitlisted patients and has been associated with early hospital re-admission, prolonged length of stay, delayed graft function and increased mortality after kidney transplantation. However, although kidney transplantation is a substantial physiological stress to a patient's reserve, by restoring kidney function, kidney transplantation has also been shown to improve a patient's frailty status. The FP is the most studied tool in patients waitlisted for transplantation, but it has not been able to distinguish those whose frailty is improved by kidney transplantation.

In summary, there remain significant gaps in knowledge and uncertainties as to how to effectively use existing frailty measures to inform decision-making around kidney transplantation. Further research is needed to address these important gaps in the literature.

虚弱是一种临床综合征,其特点是多系统功能衰退,相关的生理储备和应对压力事件的能力下降。它与医疗负担加重有关。它常见于终末期肾病(ESRD)患者。肾移植被认为是适合 ESRD 患者的最佳肾脏替代疗法。然而,手术和免疫抑制是一种生理压力,会对体弱者造成不成比例的影响。在等待肾移植的患者中,体弱正在成为一个潜在的重要风险因素。迄今为止,该领域发表的大部分研究都来自美国的一个移植中心。根据体质虚弱表型(FP)测量,体质虚弱在等待肾移植的患者中很普遍,并且与肾移植后早期再入院、住院时间延长、移植物功能延迟和死亡率增加有关。然而,虽然肾移植对患者的储备造成了巨大的生理压力,但通过恢复肾功能,肾移植也被证明可以改善患者的虚弱状态。总之,在如何有效利用现有的虚弱度测量方法为肾移植决策提供信息方面,仍然存在巨大的知识差距和不确定性。需要进一步开展研究,以填补这些重要的文献空白。
{"title":"Latest advances in frailty in kidney transplantation: A narrative review","authors":"Ruth Fergie ,&nbsp;Alexander P. Maxwell ,&nbsp;Emma L. Cunningham","doi":"10.1016/j.trre.2024.100833","DOIUrl":"10.1016/j.trre.2024.100833","url":null,"abstract":"<div><p>Frailty is a clinical syndrome that is characterised by decline in multiple systems with associated decreased physiological reserve and ability to respond to stressor events. It is associated with greater healthcare burden. It is common in patients with end-stage renal disease (ESRD). Kidney transplantation is considered the optimal form of renal replacement therapy for suitable patients with ESRD. However, surgery and immunosuppression are physiological stresses that can disproportionately affect frail individuals. Frailty is emerging as a potentially important risk factor in patients waitlisted for kidney transplantation. Most of the published research to date in this area comes from a single transplant centre in the USA. Frailty, as measured using the Physical Frailty Phenotype (FP), is prevalent in waitlisted patients and has been associated with early hospital re-admission, prolonged length of stay, delayed graft function and increased mortality after kidney transplantation. However, although kidney transplantation is a substantial physiological stress to a patient's reserve, by restoring kidney function, kidney transplantation has also been shown to improve a patient's frailty status. The FP is the most studied tool in patients waitlisted for transplantation, but it has not been able to distinguish those whose frailty is improved by kidney transplantation.</p><p>In summary, there remain significant gaps in knowledge and uncertainties as to how to effectively use existing frailty measures to inform decision-making around kidney transplantation. Further research is needed to address these important gaps in the literature.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 2","pages":"Article 100833"},"PeriodicalIF":4.0,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X24000168/pdfft?md5=d87f31ad7793c75e8420bf137961e746&pid=1-s2.0-S0955470X24000168-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139578131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The psychology, legality, ethics and medical aspects of organ donation by minors 未成年人器官捐赠的心理、合法性、伦理和医学问题
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-19 DOI: 10.1016/j.trre.2024.100832
A. Ashwin , S.D. Cherukuri , A. Rammohan

Any individual who has not attained the chronological age of legal majority as per national law is termed a minor. The concept of living donation (LD) has always been a subject of ethical debate and further compounding the controversy is the question of LD by minors. The decision for a minor to donate poses a special challenge as it involves a close family unit of parent-child relationship. Such an emotionally loaded situation wherein questions of attachment, perceived duties, moral obligation are likely to cloud a truly informed consent on the part of the minor to donation, who may find themselves in a vulnerable position. Furthermore, a minor's cognitive ability to comprehend the gravity of LD and when required defy parental coercion need to be elucidates before a minor is accepted for LD. Experts have set out stringent conditions which need to be met prior to the exceptional circumstance that a minor is considered for organ donation. Such donations should require parental permission, child's assent and the involvement of a paediatric-trained donor advocacy team. This article debates the question of minors acting as live donors from ethical, medical, psychosocial and legal viewpoints with an aim to present internationally defined circumstances when a minor may morally participate as a LD, thereby laying the foundation for future deliberations in this regard using traditional metrics to juxtapose divergent courses of action.

任何未达到国家法律规定的法定成年年龄的人都被称为未成年人。活体捐献(LD)的概念一直是伦理争论的主题,而未成年人的活体捐献问题则进一步加剧了争论。未成年人捐献的决定是一个特殊的挑战,因为它涉及到一个亲子关系密切的家庭单元。在这种充满感情的情况下,依恋、责任感、道德义务等问题很可能会影响未成年人在真正知情的情况下同意捐献,他们可能会发现自己处于弱势地位。此外,在接受未成年人捐献前,需要阐明未成年人的认知能力,以理解 LD 的严重性,并在必要时反抗父母的胁迫。专家们提出了严格的条件,未成年人在特殊情况下被考虑捐献器官之前必须满足这些条件。此类捐赠应征得父母的许可、儿童的同意,并有受过儿科训练的捐赠倡导小组的参与。本文从伦理、医学、社会心理和法律角度对未成年人作为活体捐献者的问题进行了辩论,旨在介绍国际上界定的未成年人在何种情况下可以在道义上作为活体捐献者参与捐献,从而为今后在这方面的讨论奠定基础,利用传统的衡量标准将不同的行动方案并列起来。
{"title":"The psychology, legality, ethics and medical aspects of organ donation by minors","authors":"A. Ashwin ,&nbsp;S.D. Cherukuri ,&nbsp;A. Rammohan","doi":"10.1016/j.trre.2024.100832","DOIUrl":"10.1016/j.trre.2024.100832","url":null,"abstract":"<div><p>Any individual who has not attained the chronological age of legal majority as per national law is termed a minor. The concept of living donation (LD) has always been a subject of ethical debate and further compounding the controversy is the question of LD by minors. The decision for a minor to donate poses a special challenge as it involves a close family unit of parent-child relationship. Such an emotionally loaded situation wherein questions of attachment, perceived duties, moral obligation are likely to cloud a truly informed consent on the part of the minor to donation, who may find themselves in a vulnerable position. Furthermore, a minor's cognitive ability to comprehend the gravity of LD and when required defy parental coercion need to be elucidates before a minor is accepted for LD. Experts have set out stringent conditions which need to be met prior to the exceptional circumstance that a minor is considered for organ donation. Such donations should require parental permission, child's assent and the involvement of a paediatric-trained donor advocacy team. This article debates the question of minors acting as live donors from ethical, medical, psychosocial and legal viewpoints with an aim to present internationally defined circumstances when a minor may morally participate as a LD, thereby laying the foundation for future deliberations in this regard using traditional metrics to juxtapose divergent courses of action.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 2","pages":"Article 100832"},"PeriodicalIF":4.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139496884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miRNA as potential biomarkers after liver transplantation: A systematic review miRNA 作为肝移植后的潜在生物标记物:系统综述
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-14 DOI: 10.1016/j.trre.2024.100831
Pia F. Koch , Kristina Ludwig , Felix Krenzien , Karl H. Hillebrandt , Wenzel Schöning , Johann Pratschke , Nathanael Raschzok , Igor M. Sauer , Simon Moosburner

Background

Liver transplantation is a life-saving therapy for end-stage liver disease patients, but acute cellular rejection (ACR) and graft complications remain significant postoperative challenges. Early and accurate diagnosis is crucial for timely intervention and improved patient outcomes, but their diagnosis rely currently on invasive biopsy sampling, thus prompting the search for non-invasive Biomarkers. MicroRNA (miRNA) have emerged as promising biomarkers in various pathological conditions, and their potential utility in diagnosing acute cellular rejection after liver transplantation has gained significant interest.

Methods

This systematic review of PubMed, Web of Science, and the ClinicalTrials.gov registry analyzes studies exploring miRNA as biomarkers for ACR and graft dysfunction in liver transplantation (PROSPERO ID CRD42023465278). The Cochrane Collaboration tool for assessing risk of bias was employed. Population data, identified miRNA and their dynamic regulation, as well as event prediction were compared. Data extraction and quality assessment were performed independently by two reviewers.

Results

Thirteen studies were included in this systematic review. Various investigated miRNAs were upregulated in association with acute cellular rejection, like miR-122, miR-155, miR-181, miR-483-3p, and miR-885-5p, demonstrating great biomarker potential. Additionally, several studies conducted target gene analysis, revealing insights into cellular mechanisms linked to ACR. Moreover, various miRNA were also capable of predicting different organ complications following transplantation, expanding their versatility. Remaining challenges include the standardization of miRNA profiling, the need for functional validation, and the necessity for long-term studies.

Conclusion

The results highlight the potential of miRNA as specific, non-invasive biomarkers for ACR and graft dysfunction following liver transplantation. However, further research is needed to validate these findings and establish standardized diagnostic panels to incorporate them into clinical practice and explore miRNA-based therapies in the future.

背景肝移植是挽救终末期肝病患者生命的疗法,但急性细胞排斥反应(ACR)和移植物并发症仍是术后面临的重大挑战。早期准确的诊断对于及时干预和改善患者预后至关重要,但其诊断目前依赖于侵入性活检取样,因此促使人们寻找非侵入性生物标志物。方法本系统综述对 PubMed、Web of Science 和 ClinicalTrials.gov 注册表进行了分析,探讨了 miRNA 作为肝移植(PROSPERO ID CRD42023465278)中 ACR 和移植物功能障碍生物标志物的研究。采用 Cochrane 协作工具评估偏倚风险。比较了人群数据、确定的 miRNA 及其动态调控以及事件预测。数据提取和质量评估由两名审稿人独立完成。所研究的多种 miRNAs 均与急性细胞排斥反应相关,如 miR-122、miR-155、miR-181、miR-483-3p 和 miR-885-5p,显示出巨大的生物标记潜力。此外,一些研究还进行了靶基因分析,揭示了与 ACR 相关的细胞机制。此外,各种 miRNA 还能预测移植后不同器官的并发症,从而扩大了它们的用途。结论:研究结果凸显了 miRNA 作为肝移植后 ACR 和移植物功能障碍的特异性、非侵入性生物标志物的潜力。然而,还需要进一步的研究来验证这些发现,建立标准化的诊断面板,以便将其纳入临床实践,并在未来探索基于 miRNA 的疗法。
{"title":"miRNA as potential biomarkers after liver transplantation: A systematic review","authors":"Pia F. Koch ,&nbsp;Kristina Ludwig ,&nbsp;Felix Krenzien ,&nbsp;Karl H. Hillebrandt ,&nbsp;Wenzel Schöning ,&nbsp;Johann Pratschke ,&nbsp;Nathanael Raschzok ,&nbsp;Igor M. Sauer ,&nbsp;Simon Moosburner","doi":"10.1016/j.trre.2024.100831","DOIUrl":"https://doi.org/10.1016/j.trre.2024.100831","url":null,"abstract":"<div><h3>Background</h3><p><span><span>Liver transplantation is a life-saving therapy for end-stage liver disease patients, but </span>acute cellular rejection (ACR) and graft complications remain significant postoperative challenges. Early and accurate diagnosis is crucial for timely intervention and improved patient outcomes, but their diagnosis rely currently on invasive biopsy sampling, thus prompting the search for non-invasive Biomarkers. </span>MicroRNA (miRNA) have emerged as promising biomarkers in various pathological conditions, and their potential utility in diagnosing acute cellular rejection after liver transplantation has gained significant interest.</p></div><div><h3>Methods</h3><p><span>This systematic review of PubMed, Web of Science, and the </span><span>ClinicalTrials.gov</span><svg><path></path></svg><span> registry analyzes studies exploring miRNA as biomarkers for ACR and graft dysfunction in liver transplantation (PROSPERO ID CRD42023465278). The Cochrane Collaboration tool for assessing risk of bias was employed. Population data, identified miRNA and their dynamic regulation, as well as event prediction were compared. Data extraction and quality assessment were performed independently by two reviewers.</span></p></div><div><h3>Results</h3><p>Thirteen studies were included in this systematic review. Various investigated miRNAs were upregulated in association with acute cellular rejection, like miR-122, miR-155, miR-181, miR-483-3p, and miR-885-5p, demonstrating great biomarker potential. Additionally, several studies conducted target gene analysis, revealing insights into cellular mechanisms linked to ACR. Moreover, various miRNA were also capable of predicting different organ complications following transplantation, expanding their versatility. Remaining challenges include the standardization of miRNA profiling, the need for functional validation, and the necessity for long-term studies.</p></div><div><h3>Conclusion</h3><p>The results highlight the potential of miRNA as specific, non-invasive biomarkers for ACR and graft dysfunction following liver transplantation. However, further research is needed to validate these findings and establish standardized diagnostic panels to incorporate them into clinical practice and explore miRNA-based therapies in the future.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 2","pages":"Article 100831"},"PeriodicalIF":4.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139487854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review 西班牙存在或不存在抗病毒耐药性的难治性巨细胞病毒感染的发生率:一项系统文献综述。
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.trre.2023.100804
J.M. Aguado , D. Navarro , C. Montoto , M. Yébenes , I. de Castro-Orós

Introduction

Solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) recipients are susceptible to cytomegalovirus (CMV) infection. The incidence of refractoriness to antivirals, with or without resistance, is unclear. The purpose of this review was to describe the epidemiology of refractory CMV infection in Spain to understand the current unmet needs.

Methods

PubMed, EMBASE, Cochrane and MEDES were searched systematically for relevant articles. We included randomized controlled trials and observational studies published during the period from January 1990 to June 2021.

Results

From 212 screened records, we selected 19 papers including 1973 transplant recipients. Refractory infection ranged from 3 to 10% in studies with SOT recipients. The incidence of CMV resistance ranged from 1% to 36% in these patients. The incidence of CMV refractory infection in HSCT recipients ranged from 11 to 50%, while values for resistant infection ranged from 0% to 21%.

Conclusion

The wide range of definitions and values observed does not allow us to establish the true incidence of refractory CMV infection with or without resistances in SOT and HSCT patients in Spain. This review highlights the gap between clinical practice and clinical trials' definitions which needed to be updated to be easier followed in current clinical practice.

引言:实体器官移植(SOT)和造血干细胞移植(HSCT)受者易感染巨细胞病毒(CMV)。抗病毒药物不耐受的发生率,无论是否具有耐药性,尚不清楚。本综述的目的是描述西班牙难治性巨细胞病毒感染的流行病学,以了解目前未满足的需求。方法:系统检索PubMed、EMBASE、Cochrane和MEDES等相关文献。我们纳入了1990年1月至2021年6月期间发表的随机对照试验和观察性研究。结果:从212份筛选记录中,我们选择了19篇论文,其中包括1973名移植受者。在SOT受体的研究中,难治性感染的发生率在3%至10%之间。这些患者CMV耐药性的发生率在1%至36%之间。HSCT受体中CMV难治性感染的发生率在11%至50%之间,而耐药感染的值在0%至21%之间。结论:观察到的定义和值范围广泛,无法确定西班牙SOT和HSCT患者中有或无耐药的难治性CMV感染的真实发生率。这篇综述强调了临床实践和临床试验定义之间的差距,需要更新这些定义,以便在当前临床实践中更容易遵循。
{"title":"Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review","authors":"J.M. Aguado ,&nbsp;D. Navarro ,&nbsp;C. Montoto ,&nbsp;M. Yébenes ,&nbsp;I. de Castro-Orós","doi":"10.1016/j.trre.2023.100804","DOIUrl":"10.1016/j.trre.2023.100804","url":null,"abstract":"<div><h3>Introduction</h3><p>Solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) recipients are susceptible to cytomegalovirus (CMV) infection. The incidence of refractoriness to antivirals, with or without resistance, is unclear. The purpose of this review was to describe the epidemiology of refractory CMV infection in Spain to understand the current unmet needs.</p></div><div><h3>Methods</h3><p>PubMed, EMBASE, Cochrane and MEDES were searched systematically for relevant articles. We included randomized controlled trials and observational studies published during the period from January 1990 to June 2021.</p></div><div><h3>Results</h3><p>From 212 screened records, we selected 19 papers including 1973 transplant recipients. Refractory infection ranged from 3 to 10% in studies with SOT recipients. The incidence of CMV resistance ranged from 1% to 36% in these patients. The incidence of CMV refractory infection in HSCT recipients ranged from 11 to 50%, while values for resistant infection ranged from 0% to 21%.</p></div><div><h3>Conclusion</h3><p>The wide range of definitions and values observed does not allow us to establish the true incidence of refractory CMV infection with or without resistances in SOT and HSCT patients in Spain. This review highlights the gap between clinical practice and clinical trials' definitions which needed to be updated to be easier followed in current clinical practice.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 1","pages":"Article 100804"},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X23000587/pdfft?md5=95d0c3a7473089a433942370afaf425c&pid=1-s2.0-S0955470X23000587-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72212491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
British Transplantation Society guidelines on abdominal organ transplantation from deceased donors after circulatory death 英国移植学会关于循环系统死亡后已故捐赠者腹部器官移植的指南。
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.trre.2023.100801
Benedict Phillips , Ellie Asgari , Miriam Berry , Chris Callaghan , Miriam Cortes Cerisuelo , Paul Johnson , Nikolaos Karydis , David Nasralla , Anisa Nutu , Gabi Oniscu , Thamara Perera , Sanjay Sinha , Andrew Sutherland , David Van Dellen , Chris Watson , Steve White , Stephen O'Neill

The British Transplantation Society (BTS) ‘Guideline on transplantation from deceased donors after circulatory death’ has recently been updated and this manuscript summarises the relevant recommendations in abdominal organ transplantation from Donation after Circulatory Death (DCD) donors, encompassing the chapters on liver, kidney, pancreas and islet cell transplantation.

英国移植学会(BTS)最近更新了“循环死亡后已故捐赠者移植指南”,该手稿总结了循环死亡后捐赠捐赠者腹部器官移植的相关建议,包括肝、肾、胰腺和胰岛细胞移植章节。
{"title":"British Transplantation Society guidelines on abdominal organ transplantation from deceased donors after circulatory death","authors":"Benedict Phillips ,&nbsp;Ellie Asgari ,&nbsp;Miriam Berry ,&nbsp;Chris Callaghan ,&nbsp;Miriam Cortes Cerisuelo ,&nbsp;Paul Johnson ,&nbsp;Nikolaos Karydis ,&nbsp;David Nasralla ,&nbsp;Anisa Nutu ,&nbsp;Gabi Oniscu ,&nbsp;Thamara Perera ,&nbsp;Sanjay Sinha ,&nbsp;Andrew Sutherland ,&nbsp;David Van Dellen ,&nbsp;Chris Watson ,&nbsp;Steve White ,&nbsp;Stephen O'Neill","doi":"10.1016/j.trre.2023.100801","DOIUrl":"10.1016/j.trre.2023.100801","url":null,"abstract":"<div><p>The British Transplantation Society (BTS) ‘Guideline on transplantation from deceased donors after circulatory death’ has recently been updated and this manuscript summarises the relevant recommendations in abdominal organ transplantation from Donation after Circulatory Death (DCD) donors, encompassing the chapters on liver, kidney, pancreas and islet cell transplantation.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 1","pages":"Article 100801"},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X23000551/pdfft?md5=afb7709f0a4d3e899e136f32e3860e6b&pid=1-s2.0-S0955470X23000551-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The British Transplantation Society guidelines on ethics, law and consent in relation to deceased donors after circulatory death 英国移植学会关于循环系统死亡后已故捐赠者的伦理、法律和同意的指导方针。
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.trre.2023.100803
Greg Moorlock , Ellie Asgari , Chris Callaghan , Heather Draper , Peter Dupont , Patty Gilbert , David Nasralla , Peter Veitch , Chris Watson , Stephen O'Neill

The British Transplantation Society (BTS) ‘Guideline on transplantation from deceased donors after circulatory death’ has recently been updated and this manuscript summarises the relevant recommendations from chapters specifically related to law, ethics, donor consent and informing the recipient.

英国移植学会(BTS)最近更新了《循环系统死亡后已故捐赠者移植指南》,该手稿总结了专门与法律、伦理、捐赠者同意和告知接受者有关的章节中的相关建议。
{"title":"The British Transplantation Society guidelines on ethics, law and consent in relation to deceased donors after circulatory death","authors":"Greg Moorlock ,&nbsp;Ellie Asgari ,&nbsp;Chris Callaghan ,&nbsp;Heather Draper ,&nbsp;Peter Dupont ,&nbsp;Patty Gilbert ,&nbsp;David Nasralla ,&nbsp;Peter Veitch ,&nbsp;Chris Watson ,&nbsp;Stephen O'Neill","doi":"10.1016/j.trre.2023.100803","DOIUrl":"10.1016/j.trre.2023.100803","url":null,"abstract":"<div><p>The British Transplantation Society (BTS) ‘Guideline on transplantation from deceased donors after circulatory death’ has recently been updated and this manuscript summarises the relevant recommendations from chapters specifically related to law, ethics, donor consent and informing the recipient.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 1","pages":"Article 100803"},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X23000575/pdfft?md5=e5777b0b6f91874ca342be5ac81ddeb4&pid=1-s2.0-S0955470X23000575-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary and esophageal function in lung transplantation: Fundamental principles and clinical application 肺移植中的肺和食管功能:基本原理和临床应用。
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.trre.2023.100796
Andrés R. Latorre-Rodríguez , Deepika Razia , Ashraf Omar , Ross M. Bremner , Sumeet K. Mittal

The lungs and esophagus have a close anatomical and physiological relationship. Over the years, reflux-induced pulmonary injury has gained wider recognition, but the full effects of pulmonary disease on esophageal function are still unknown. Intrathoracic pressure dynamics potentially affect esophageal function, especially in patients with end-stage lung disease, both obstructive and restrictive. Lung transplantation is the only viable option for patients with end-stage pulmonary disease and has provided us with a unique opportunity to study these effects as transplantation restores the intrathoracic environment. Esophageal and foregut functional testing before and after transplantation provide insights into the pathophysiology of the foregut-pulmonary axis, such as how underlying pulmonary disease and intrathoracic pressure changes affect esophageal physiology. This review summarizes the available literature and shares the research experience of a lung transplant center, covering topics such as pre- and posttransplant foregut function, esophageal motility in lung transplant recipients, immune-mediated mechanisms of graft rejection associated with gastroesophageal reflux, and the role of antireflux surgery in this population.

肺和食道在解剖学和生理学上有着密切的关系。多年来,反流性肺损伤已经得到了广泛的认识,但肺部疾病对食管功能的全面影响仍然未知。胸腔内压力动力学可能会影响食道功能,尤其是在患有阻塞性和限制性终末期肺病的患者中。肺移植是终末期肺病患者唯一可行的选择,它为我们提供了一个独特的机会来研究这些影响,因为移植可以恢复胸腔内环境。移植前后的食道和前肠功能测试可以深入了解前肠肺轴的病理生理学,例如潜在的肺部疾病和胸内压力变化如何影响食道生理学。这篇综述总结了现有的文献,并分享了肺移植中心的研究经验,涵盖了移植前和移植后前肠功能、肺移植受者的食管运动、与胃食管反流相关的移植物排斥反应的免疫介导机制,以及抗反流手术在该人群中的作用等主题。
{"title":"Pulmonary and esophageal function in lung transplantation: Fundamental principles and clinical application","authors":"Andrés R. Latorre-Rodríguez ,&nbsp;Deepika Razia ,&nbsp;Ashraf Omar ,&nbsp;Ross M. Bremner ,&nbsp;Sumeet K. Mittal","doi":"10.1016/j.trre.2023.100796","DOIUrl":"10.1016/j.trre.2023.100796","url":null,"abstract":"<div><p><span><span>The lungs and esophagus have a close anatomical and physiological relationship. Over the years, reflux-induced pulmonary injury has gained wider recognition, but the full effects of pulmonary disease on </span>esophageal function<span> are still unknown. Intrathoracic pressure dynamics potentially affect esophageal function, especially in patients with end-stage lung disease, both obstructive and restrictive. </span></span>Lung transplantation<span><span><span><span> is the only viable option for patients with end-stage pulmonary disease and has provided us with a unique opportunity to study these effects as transplantation restores the intrathoracic environment. Esophageal and foregut functional testing before and after transplantation provide insights into the </span>pathophysiology of the foregut-pulmonary axis, such as how underlying pulmonary disease and intrathoracic pressure changes affect esophageal physiology. This review summarizes the available literature and shares the research experience of a lung transplant center, covering topics such as pre- and posttransplant foregut function, </span>esophageal motility in lung transplant recipients, immune-mediated mechanisms of </span>graft rejection<span><span> associated with gastroesophageal reflux, and the role of </span>antireflux surgery in this population.</span></span></p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 1","pages":"Article 100796"},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress in preservation of intestinal grafts by oxygenated hypothermic machine perfusion 充氧低温机械灌注保存肠移植物的研究进展。
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.trre.2023.100802
Shuang Yang , Wen Hou , Lei Liu

Intestine transplantation (IT) is a critical treatment strategy for irreversible intestinal failure. Among all abdominal solid organ transplants, the intestine was the most vulnerable to ischemia and reperfusion injury (IRI). The static cold storage (SCS) technique is currently the most commonly used graft preservation method, but its hypoxia condition causes metabolic disorders, resulting in the occurrence of IRI, limiting its application in marginal organs. It is especially important to improve preservation techniques in order to minimize damage to marginal donor organs, which draws more attention to machine perfusion (MP). There has been much debate about whether it is necessary to increase oxygen in these conditions to support low levels of metabolism since the use of machine perfusion to preserve organs. There is evidence that oxygenation helps to restore intracellular ATP levels in the intestine after thermal or cold ischemia damage. The goal of this review is to provide an overview of the role of oxygen in maintaining environmental stability in the gut under hypoxic conditions, as well as to investigate the possibilities and mechanisms of oxygen delivery during preservation in intestine transplantation studies and clinical models.

肠移植是治疗不可逆性肠功能衰竭的重要策略。在所有腹部实体器官移植中,肠道最容易受到缺血再灌注损伤(IRI)的影响。静态冷藏(SCS)技术是目前最常用的移植物保存方法,但其缺氧条件会导致代谢紊乱,导致IRI的发生,限制了其在边缘器官中的应用。改进保存技术以最大限度地减少对边缘供体器官的损伤尤为重要,这引起了人们对机器灌注(MP)的更多关注。自从使用机器灌注来保存器官以来,人们一直在争论是否有必要在这些条件下增加氧气以支持低水平的代谢。有证据表明,在热缺血或冷缺血损伤后,氧合有助于恢复肠道中的细胞内ATP水平。这篇综述的目的是概述氧气在缺氧条件下维持肠道环境稳定的作用,并研究在肠道移植研究和临床模型中保存期间氧气输送的可能性和机制。
{"title":"Progress in preservation of intestinal grafts by oxygenated hypothermic machine perfusion","authors":"Shuang Yang ,&nbsp;Wen Hou ,&nbsp;Lei Liu","doi":"10.1016/j.trre.2023.100802","DOIUrl":"10.1016/j.trre.2023.100802","url":null,"abstract":"<div><p>Intestine transplantation (IT) is a critical treatment strategy for irreversible intestinal failure. Among all abdominal solid organ transplants, the intestine was the most vulnerable to ischemia and reperfusion injury (IRI). The static cold storage (SCS) technique is currently the most commonly used graft preservation method, but its hypoxia condition causes metabolic disorders, resulting in the occurrence of IRI, limiting its application in marginal organs. It is especially important to improve preservation techniques in order to minimize damage to marginal donor organs, which draws more attention to machine perfusion (MP). There has been much debate about whether it is necessary to increase oxygen in these conditions to support low levels of metabolism since the use of machine perfusion to preserve organs. There is evidence that oxygenation helps to restore intracellular ATP levels in the intestine after thermal or cold ischemia damage. The goal of this review is to provide an overview of the role of oxygen in maintaining environmental stability in the gut under hypoxic conditions, as well as to investigate the possibilities and mechanisms of oxygen delivery during preservation in intestine transplantation studies and clinical models.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 1","pages":"Article 100802"},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X23000563/pdfft?md5=33beba80b0cef6199ae6749a374b64c6&pid=1-s2.0-S0955470X23000563-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61567122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunosuppression for older liver transplant recipients 老年肝移植受者的免疫抑制
IF 4 2区 医学 Q2 IMMUNOLOGY Pub Date : 2023-12-16 DOI: 10.1016/j.trre.2023.100817
Paolo De Simone , Sara Battistella , Quirino Lai , Juri Ducci , Francesca D'Arcangelo , Piero Marchetti , Francesco Paolo Russo , Patrizia Burra

Older liver transplant recipients have a lower risk of acute rejection than younger patients (9% for patients aged ≥65 years versus 23% for those aged 18–34 years) and are more vulnerable to immunosuppression-related complications. The number of liver transplant recipients ≥65 years has risen to 22% in Europe and the US, but limited information is available on the optimal immunosuppressive regimen for these patients. In this review, we discuss the appropriate management of immunosuppressive agents in older adults to minimize adverse events while avoiding acute rejection. The way the body processes drugs greatly depends on age. In the case of calcineurin inhibitor drugs, aging reduces hepatic metabolism, leading to changes in their pharmacokinetics. Corticosteroids also show decreased clearance as the patient ages. In severe cases of hypoalbuminemia, dose adjustment of mycophenolate acid derivatives may be necessary. However, the pharmacokinetic profiles of the mammalian target of rapamycin inhibitors, basiliximab, and rabbit anti-thymocyte globulin remain unaffected by age. Furthermore, age-related frailty may impact drug metabolism and require tailored interventions and closer follow-up. Although there is limited research, elderly liver transplant recipients require less immunosuppression with double or triple-agent regimens, lower exposure to calcineurin inhibitors, and a shorter course of corticosteroids. The usage of mammalian target of rapamycin inhibitors in older transplant populations has not been specifically investigated, and thus their usage should align with indications for younger patient groups.

与年轻患者相比,老年肝移植受者发生急性排斥反应的风险较低(年龄≥65 岁的患者为 9%,而 18-34 岁的患者为 23%),而且更容易出现免疫抑制相关并发症。在欧洲和美国,年龄≥65 岁的肝移植受者人数已上升至 22%,但有关这些患者最佳免疫抑制方案的信息却很有限。在这篇综述中,我们将讨论如何适当管理老年人的免疫抑制剂,以尽量减少不良反应,同时避免急性排斥反应。人体处理药物的方式在很大程度上取决于年龄。就钙调磷酸酶抑制剂药物而言,衰老会降低肝脏代谢,从而导致其药代动力学发生变化。皮质类固醇的清除率也会随着患者年龄的增长而降低。严重的低白蛋白血症患者可能需要调整霉酚酸衍生物的剂量。然而,雷帕霉素哺乳动物靶点抑制剂、巴西利昔单抗和兔抗胸腺细胞球蛋白的药代动力学特征不受年龄影响。此外,与年龄有关的虚弱可能会影响药物代谢,因此需要有针对性的干预措施和更密切的随访。虽然研究有限,但老年肝移植受者需要的双药或三药免疫抑制较少,接触钙神经蛋白抑制剂的机会较低,皮质类固醇的疗程也较短。哺乳动物雷帕霉素靶点抑制剂在老年移植人群中的使用情况尚未得到专门研究,因此其使用应与年轻患者群体的适应症相一致。
{"title":"Immunosuppression for older liver transplant recipients","authors":"Paolo De Simone ,&nbsp;Sara Battistella ,&nbsp;Quirino Lai ,&nbsp;Juri Ducci ,&nbsp;Francesca D'Arcangelo ,&nbsp;Piero Marchetti ,&nbsp;Francesco Paolo Russo ,&nbsp;Patrizia Burra","doi":"10.1016/j.trre.2023.100817","DOIUrl":"10.1016/j.trre.2023.100817","url":null,"abstract":"<div><p><span><span><span>Older liver transplant<span> recipients have a lower risk of acute rejection than younger patients (9% for patients aged ≥65 years versus 23% for those aged 18–34 years) and are more vulnerable to immunosuppression-related complications. The number of liver transplant recipients ≥65 years has risen to 22% in Europe and the US, but limited information is available on the optimal </span></span>immunosuppressive regimen for these patients. In this review, we discuss the appropriate management of immunosuppressive agents in older adults to minimize adverse events while avoiding acute rejection. The way the body processes </span>drugs<span><span><span> greatly depends on age. In the case of calcineurin inhibitor drugs, aging reduces hepatic metabolism, leading to changes in their </span>pharmacokinetics. Corticosteroids also show decreased clearance as the patient ages. In severe cases of </span>hypoalbuminemia, dose adjustment of </span></span>mycophenolate<span><span><span> acid derivatives may be necessary. However, the pharmacokinetic profiles of the mammalian target of rapamycin inhibitors, </span>basiliximab, and rabbit anti-thymocyte globulin remain unaffected by age. Furthermore, age-related </span>frailty<span> may impact drug metabolism and require tailored interventions and closer follow-up. Although there is limited research, elderly liver transplant recipients require less immunosuppression with double or triple-agent regimens, lower exposure to calcineurin inhibitors, and a shorter course of corticosteroids. The usage of mammalian target of rapamycin inhibitors in older transplant populations has not been specifically investigated, and thus their usage should align with indications for younger patient groups.</span></span></p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"38 1","pages":"Article 100817"},"PeriodicalIF":4.0,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138744608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Transplantation Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1